http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Monabati, Ahmad (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
Monabati, Ahmad,Vahedi, Amir,Safaei, Akbar,Noori, Sadat,Mokhtari, Maral,Vahedi, Leila,Zamani, Mehdi Asian Pacific Journal of Cancer Prevention 2016 Asian Pacific journal of cancer prevention Vol.17 No.4
Background: Epstein-Barr virus (EBV) positive diffuse large B-cell lymphoma (DLBCL) of the elderly is an entity introduced in the latest WHO classification of lymphoid tumors and defined in patients older than 50 years without prior lymphoma or immunodeficiency. However, recently it has also been seen in patients under 50. There is thus debate as to whether these are separate entities. Materials and Methods: In this retrospective study, we analyzed de novo DLBCL admitted to our institute over a period of two years. Clinical data included age, sex, nodal and extranodal presentation. The results of an immunohistochemistry (IHC) panel were also reviewed. IHC findings were mainly used to sub-classify DLBCL as germinal center vs. non germinal center types. IHC for identification of LMP-1 (latent membrane protein) and in situ hybridization for detection of EBV-encoded RNA (EBER) was performed. EBV prevalence, clinical data and IHC findings were compared between patients under and over 50 years of age. Results: Out of 95 DLBCL, 11.6% were EBV positive (7.5% and 14.5% in the young and old groups). We did not find any significant differences in IHC subclasses and clinical data between EBV positive DLBCL (EBV+DLBCL) of young and old groups. Conclusions: EBV+DLBCL are not exclusive to patients older than 50 years. With regard to clinical data as well as IHC subclasses, no differences were evident between EBV+DLBCL of young and old groups. Our suggestion is to eliminate any cut off age for EBV+DLBCL.
-
Akbar Safaei,Ahmad Monabati,Moeinadin Safavi,Ali Atashabparvar,Marzieh Hosseini 대한혈액학회 2018 Blood Research Vol.53 No.1
BackgroundAdditional cytogenetic aberrations are associated with disease progression in chronicmyeloid leukemia (CML). This study was conducted to determine the type and frequencyof these aberrations and their relationship with hematologic and molecular findings inthe Middle East. MethodsIn this retrospective study, 134 well-established cases of CML were selected from 2010to 2016. Their hematologic phase and type of fusion gene were determined. Finally, theirkaryotypes were analyzed and reported according to ISCN 2013. ResultsPatients had a mean age of 44 years. Twenty-two patients (16.4%) showed additional cytogeneticaberrations. Nine patients (6.7%) harbored a variant Philadelphia chromosome,and most were in the chronic phase. Seventeen patients (12.7%) had major and minorroute abnormalities. There was a significant relationship between additional cytogeneticaberrations and major molecular response (P=0.032). Patient survival in the group withadditional cytogenetic aberrations was significantly lower (49.7±11.1 mo) than that inthe group without additional cytogenetic aberrations (77.3±3.1 mo) (P=0.031). ConclusionThis study revealed the same frequency of additional cytogenetic aberrations in CML asfound in previous studies. Additional chromosomal aberrations led to shorter survivaland lower rates of achievement of a major molecular response.
-
Nargess Arandi,Mani Ramzi,Fatemeh Safaei,Ahmad Monabati 대한혈액학회 2018 Blood Research Vol.53 No.4
BackgroundProduction of immunosuppressive enzymes such as indoleamine 2,3-dioxygenase (IDO) is one of the strategies employed by hematologic malignancies, including acute myeloid leukemia (AML), to circumvent immune surveillance. Moreover, IDO has the ability to convert CD4+CD25- conventional T cells into regulatory T cells (Tregs). In this study, we evaluated the expression of IDO in cytogenetically normal acute myeloid leukemia (CN-AML) patients and its correlation with the Treg marker, FOXP3, as well as clinical and laboratory parameters.MethodsThirty-seven newly diagnosed CN-AML patients were enrolled in our study along with 22 healthy individuals. The expression of the IDO and FOXP3 genes was analyzed by SYBR Green real-time PCR.ResultsBoth IDO and FOXP3 were highly upregulated in CN-AML patients compared to control groups (P=0.004 and P=0.031, respectively). A positive correlation was observed be-tween IDO and FOXP3 expression among AML patients (r=0.512, P=0.001). Expression of IDO and FOXP3 showed no significant correlation with laboratory parameters such as white blood cell and platelet counts, hemoglobin levels, bone marrow blast percent-age, gender, and FLT3 mutation status (P>0.05).ConclusionHigher IDO expression in CN-AML patients may be associated with an increased Treg phenotype which may promote disease progression and lead to poor prognosis of CN-AML patients.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
